and commercialize new generation irradiators for ensuring the safety of blood transfusions by
replacing cesium, 137 which is identified as a national security hazard.
Moreover, the Advancing Transfusion Cellular Therapies Worldwide (AABB) works in
collaboration with the Food and Drug Administration (FDA) to ensure appropriate irradiation
guidance and regulations for blood products, thereby favoring the blood irradiators market by
maintaining security and compliance to limit the use of radioactive irradiators.
However, the lack of awareness among population regarding uses and benefits of irradiators in the
healthcare facilities and high cost of the irradiators are the factors hindering the market growth. For
instance, according to the survey by College of American Pathologists, 2017, the cost of X-ray
irradiators is around US$ 250,000 to US$ 300,000, with annual service contract accounting for US$
15,000 to US$ 20,000.
Blood Irradiator Market - Regional Insights
On the basis of region, the global blood irradiator market is segmented into North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominant position in
the global blood irradiators market, owing to the launch and adoption of novel technologies. For
instance, in September 2017, Typenex Medical, launched Rad-Control, a new irradiation indicator
tag technology in the blood banks and blood centers in the U.S. and Canada. Rad-control ensures
that blood component has received irradiation, thereby preventing life threatening transfusion-
associated Graft-vs.-Host Disease (TA-GvHD).
For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/blood-
irradiator-market-1972
Furthermore, increasing adoption of X-ray irradiators is expected to fuel the blood irradiator market
growth. In 2017, the U.S. Department of Energy’s National Nuclear Security Administration (DOE/
NNSA) partnered with the New York City Department of Health and Mental Hygiene (DOHMH)
and the Nuclear Threat Initiative (NTI) to replace the radioactive irradiators with the safer X-ray
alternatives.
Moreover, increasing number of cases requiring blood transfusions related to various diseases in the
region is a major factor favoring the market growth. According to the American National Red
Cross, sickle cell disease affects 90,000 to 100,000 people in the U.S., and about 1,000 babies are
born with the disease annually. The sickle cell patients mostly require blood transfusions throughout
their lives. Also, according to the American Cancer Society, about 1.7 million people are expected
to be diagnosed with cancer in 2017, where the patients require blood during the chemotherapy
treatment.
Moreover, high adoption of blood irradiators in the medical settings to prevent and control the
transmission of transfusion associated graft-versus-host disease (TA-GVHD) is expected to propel
market growth in the North America. According to the Department of Health and Human Services,
2013, around 500 blood irradiators irradiated around 2 million blood units in 2013.
Blood Irradiator Market - Competitive Landscape
Key players in the global blood irradiator market are focused on strategic mergers and acquisitions
to promote the blood irradiators in the global market. For instance, Charter Medical collaborated
with RadTag Technologies to distribute the RadTag blood irradiator indicators in the U.S.
Some of the key players operating in the global blood irradiator market include Rad Source
Technologies, Sukosol Group, Typenex Medical, Gamma-Service Medical GmbH, Cegelec NDT-
PES, and Best Theratronics, Ltd.